Heidi Hagen
Director/Board Member chez VERICEL CORPORATION
Fortune : 803 709 $ au 31/03/2024
Profil
Heidi M.
Hagen founded Vineti, Inc., where she worked as Chief Strategy Officer from 2015 to 2021.
Ms. Hagen also currently works at Vericel Corp., as Independent Director from 2013, Obsidian Therapeutics, Inc., as Director, and A-Alpha Bio, Inc., as Independent Director from 2023.
Ms. Hagen also formerly worked at Alaunos Therapeutics, Inc., as Independent Director in 2021, Lykan Biosciences LLC, as Director, Dendreon Corp., as Senior Vice President-Operations from 2002 to 2012, ZappRx, Inc., as Chief Operating & Commercial Officer in 2015, Sotio LLC, as Global Chief Operating Officer from 2013 to 2014, Sonoma Biotherapeutics, Inc., as Chief Technical Officer, and Sotio Biotech AS, as Global Chief Operating Officer.
Ms. Hagen received her graduate degree in 1993 from the University of Washington, undergraduate degree in 1990 from the University of Washington, and Masters Business Admin degree in 2001 from the University of Washington.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VERICEL CORPORATION
0,03% | 08/03/2024 | 15 450 ( 0,03% ) | 803 709 $ | 31/03/2024 |
Postes actifs de Heidi Hagen
| Sociétés | Poste | Début |
|---|---|---|
| VERICEL CORPORATION | Director/Board Member | 23/08/2013 |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Director/Board Member | - |
A-Alpha Bio, Inc.
 A-Alpha Bio, Inc. Packaged SoftwareTechnology Services A-Alpha Bio, Inc. designs and develops a drug discovery platform. The firm offers AlphaSeq platform. The company was founded by Randolph Lopez and David Younger in 2017 and is headquartered in Seattle, WA. | Director/Board Member | 27/06/2023 |
Anciens postes connus de Heidi Hagen
| Sociétés | Poste | Fin |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Chief Executive Officer | 30/08/2021 |
Vineti, Inc.
 Vineti, Inc. Medical/Nursing ServicesHealth Services Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA. | Founder | 01/02/2021 |
ZappRx, Inc.
 ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA. | Chief Operating Officer | 01/06/2015 |
| Sotio LLC | Chief Operating Officer | 01/04/2014 |
| DENDREON CORPORATION | Chief Operating Officer | 01/05/2012 |
Formation de Heidi Hagen
| University of Washington | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VERICEL CORPORATION | Health Technology |
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
ZappRx, Inc.
ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA. | Commercial Services |
| Sotio LLC | |
Vineti, Inc.
Vineti, Inc. Medical/Nursing ServicesHealth Services Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA. | Health Services |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
A-Alpha Bio, Inc.
A-Alpha Bio, Inc. Packaged SoftwareTechnology Services A-Alpha Bio, Inc. designs and develops a drug discovery platform. The firm offers AlphaSeq platform. The company was founded by Randolph Lopez and David Younger in 2017 and is headquartered in Seattle, WA. | Technology Services |
Sonoma Biotherapeutics, Inc.
 Sonoma Biotherapeutics, Inc. BiotechnologyHealth Technology Sonoma Biotherapeutics, Inc. provides research, development, and manufacturing capabilities in cell therapy and genetic engineering. The company was founded by Jeffrey A. Bluestone, Fred Ramsdell, Alexander Rudensky, and Qizhi Tang in 2019 and is headquartered in South San Francisco, CA. | Health Technology |
| Lykan Biosciences LLC | |
Sotio Biotech AS
 Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Health Technology |
